SUBSCRIBE
SUBSCRIBE
Dan Samorodnitsky

Dan Samorodnitsky

News Editor

Dan Samorodnitsky is the news editor at BioSpace. He has a decade of experience covering biotech, genetics and medicine. Before coming to BioSpace he was an editor at Drug Discovery News and Massive Science, and his writing has appeared in outlets such as Quanta, STAT, GROW and many others. He is based in Minneapolis. You can reach him at dan.samorodnitsky@biospace.com.

Podcast
Tariffs Continue to Dominate Q1 Earnings, AACR Excites Cancer Space, CEO Pay Gaps, More
As Q1 2025 earnings season continues, tariffs remain top of mind for pharma CEOs and investors. Meanwhile, the American Association for Cancer Research’s annual event kicks off this year’s oncology conference season. Plus, will the FDA become politicized under HHS Secretary RFK Jr.?
April 30, 2025
 · 
1 min read
 · 
Heather McKenzie
Artificial skin technology linear icon. Editable stroke. Minimalist medical concept. Medical innovation for tissue regeneration and wound healing. Vector illustration isolated on a white background.
Rare diseases
Abeona Gets FDA Nod for Rare Skin Disease Gene Therapy
The condition, recessive dystrophic epidermolysis bullosa, causes chronic wounds and has an 84% mortality rate by age 40.
April 29, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Contemporary art collage. Hand put money to golden stack of coins, meaning income from investment. Concept of business strategy, investment, development, market, finance.
Mergers & acquisitions
Merck KGaA Moves Ahead on SpringWorks Buy for $3.9B
The transaction is expected to close in the second half of 2025. With the deal, Merck KGaA is adding to its rare disease and oncology pipelines.
April 28, 2025
 · 
3 min read
 · 
Tristan Manalac
Contemporary art collage. Creative design. Illusion hand cutting rope that man climbing up. Professional challenges and competition. Concept of business, creativity, surrealism, growth, motivation
Layoffs
Caribou Changes Course Again, Lays Off 32% of Workforce
The cell and gene therapy company is cutting 47 employees and its entire lupus program to focus resources on two CAR Ts. The move follows a reconfiguration last year to move into immunology.
April 25, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
White arrow on circle wooden move on different direction with black arrow on cube for business and technology disruption concept.
Earnings
BMS Reports Mixed Earnings as Growth Portfolio Makes Up for Generic Pressure
Despite a dip in sales and a recent schizophrenia stumble, the company drew an optimistic outlook for sales for the rest of the year, even as the specter of pharmaceutical tariffs looms.
April 24, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Piggy bank rocket launcher with smoke trail on blue background. Savings growth concept. 3D Rendering, 3D Illustration
Startups
Etiome Steps Out of Stealth With $50M to Address Disease At The ‘Silent Stage’
With a new raise provided by Flagship Pioneering, the new company is aiming to find “the silent window” before disease symptoms set in.
April 24, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Creative sketch collage of business people handshake gesture approval project development success colleagues cooperation support.
Deals
Genentech Offers up to $765M in Biobucks to Repertoire for I&I Drug Discovery
Roche’s Genentech is betting on the Flagship Pioneering–founded company’s discovery platform called DECODE to find new targets for an undisclosed autoimmune disorder.
April 23, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Podcast
Makary’s First Interview, US Manufacturing Push and Lilly vs. Novo in Obesity Pill Race
FDA Commissioner Marty Makary talks about his plans to revamp drug development and reduce ‘conflicts of interest’ between the agency and pharma industry; Roche and Regeneron jump on the U.S. manufacturing train as Trump’s tariffs loom; and Eli Lilly scores a big win for orforglipron while Novo Nordisk reveals it has applied for FDA approval of its oral semaglutide.
April 23, 2025
 · 
1 min read
 · 
Heather McKenzie
Closeup of businessman give money to robot. Man pass banknote bribe to robotic assistant. AI and technology. Vector illustration.
Artificial intelligence
Sanofi Bets More Than $1.8 Billion in Biobucks on AI-Developed Bispecifics
The French pharma giant has made multiple trips to the artificial intelligence well over the past few years, this time with Delaware-based Earendial Labs.
April 17, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
ASD autism neurodevelopmental spectrum disorder, deficits in social communication and interaction, brain with impairment, hypersensitivity and abnormalities
Editorial
Kennedy’s Hunt for a Connection Between Vaccines and Autism Is a Sham
The Health and Human Services Secretary said that he will find and eliminate the cause of autism by September, an idea that suggests how little he knows about the condition.
April 17, 2025
 · 
3 min read
 · 
Dan Samorodnitsky
Find understanding between people. Reach your opponent. Building a bridge of understanding and reasoning. Discover common ground. Pave way for cooperation or peaceful disagreement. Resolving conflict
Mergers & acquisitions
Bluebird’s Second Suitor, Ayrmid, Fails To Produce an Offer
Despite making an unsolicited bid for gene therapy maker bluebird bio, Ayrmid failed to deliver a binding offer after weeks of due diligence. Bluebird’s board recommended that it go with Carlyle and SK Capital Partner’s original offer to take the company private for $30 million.
April 16, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Art 3d banner collage of business people dollar roll cooperation success payment capital profit transaction money corruption.
Rare diseases
Glycomine Gets $115M Series C for Rare Disease, Aims for Phase II Launch Mid-Year
The raise will go toward trialing the company’s lead drug for phosphomannomutase-2 congenital disorder of glycosylation, a rare disease that affects the entire body and produces a wide range of symptoms.
April 16, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Podcast
Tariff Turmoil, FDA’s Future, Pfizer’s Obesity Setback and CEO Salaries Revealed
Donald Trump takes biopharma on a tariff-themed rollercoaster ride; J&J kicks off the Q1 earnings season; experts express concern about the FDA’s future; Pfizer’s obesity setback could be Viking’s gain; and BioSpace reveals the highest paid pharma CEOs.
April 16, 2025
 · 
1 min read
 · 
Heather McKenzie
Scientists working with DNA. Doctors doing laboratory research. Medicine and technology. Genetic testing DNA testing genetic diagnosis concept. Vector, illustration, esp.
Gene editing
Verve’s Base Editor ‘Numerically Beats’ Other Cholesterol-Lowering Drugs
In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli Lilly and a showdown with Novartis.
April 14, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Podcast
Tariff-Triggered Recession Fears, Fallout From HHS Cuts, Knockoff GLP-1s and More
A consumer-driven weight loss market could put pharma at greater risk if a recession hits; the continued turmoil at FDA and other HHS agencies magnifies the uncertainty facing the industry; Lilly files a lawsuit against a med spa selling its drugs; and more.
April 9, 2025
 · 
1 min read
 · 
Heather McKenzie
Load More